Cassava Sciences (NASDAQ: SAVA) details 2025 executive bonuses and simufilam TSC focus

Rhea-AI Filing Summary

Cassava Sciences, Inc. reported that its Board of Directors approved cash bonus awards for calendar 2025 for two named executive officers. The President & Chief Executive Officer, Richard J. Barry, was awarded a cash bonus of $355,000, and the Chief Financial Officer, Eric J. Schoen, was awarded a cash bonus of $215,000, in recognition of their contributions to the company.

For 2025, the Board set performance measures and goals that it described as challenging yet achievable with strong management performance. These goals focus on exploring the use of simufilam in Tuberous Sclerosis Complex (TSC)-related epilepsy, building a team with appropriate expertise in TSC-related epilepsy, and managing budgeting and expenses.

false 0001069530 0001069530 2025-12-12 2025-12-12

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 12, 2025

Cassava Sciences, Inc.

(Exact name of registrant as specified in its charter)

Delaware	001-41905	91-1911336
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification Number)

6801 N Capital of Texas Highway, Building 1; Suite 300

Austin, Texas 78731

(Address of principal executive offices, including zip code)

(512) 501-2444

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

☐	Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17CFR 240.14d-2(b))
☐	Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.001 par value		SAVA		Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On December 12, 2025, the Board of Directors (the “Board”) of Cassava Sciences, Inc. (the “Company”) approved cash bonus awards for calendar 2025 for the Company’s named executive officers in recognition of their contributions to the Company as follows:

Name	Title	Bonus Amount
Richard J. Barry	President & Chief Executive Officer	$                 355,000
Eric J. Schoen	Chief Financial Officer	$                 215,000

For 2025, the Board established performance measures and goals which were designed to be challenging yet achievable with strong management performance, focused primarily on (1) exploring the use of simufilam in Tuberous Sclerosis Complex (TSC)-related epilepsy, (2) building a team with appropriate expertise in TSC-related epilepsy, and (3) budgeting and expense management.

Item 9.01. Financial Statements and Exhibits.

Exhibit No.		Description
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	CASSAVA SCIENCES, INC.
	a Delaware corporation
Date: December 17, 2025
	By:	/s/  Eric J. Schoen
		Eric J. Schoen
		Chief Financial Officer

FAQ

What executive bonuses did Cassava Sciences (SAVA) approve for 2025?

Cassava Sciences approved 2025 cash bonus awards of $355,000 for President & Chief Executive Officer Richard J. Barry and $215,000 for Chief Financial Officer Eric J. Schoen, in recognition of their contributions.

What performance goals did Cassava Sciences (SAVA) set for 2025 related to these bonuses?

For 2025, the Board set performance measures focused on exploring the use of simufilam in TSC-related epilepsy, building a team with expertise in TSC-related epilepsy, and budgeting and expense management.

Which executives at Cassava Sciences (SAVA) are covered by the 2025 cash bonus awards?

The 2025 cash bonus awards disclosed apply to two named executive officers: Richard J. Barry, President & Chief Executive Officer, and Eric J. Schoen, Chief Financial Officer.

How does Cassava Sciences describe the difficulty of its 2025 performance measures?

The Board stated that the 2025 performance measures and goals were designed to be challenging yet achievable with strong management performance.

What therapeutic focus is highlighted in Cassava Sciences' 2025 performance goals?

The performance goals highlight exploring the use of simufilam in Tuberous Sclerosis Complex (TSC)-related epilepsy and building a team with expertise in this area.

On which market is Cassava Sciences (SAVA) common stock listed?

Cassava Sciences' common stock, par value $0.001 per share, is listed on the Nasdaq Capital Market under the trading symbol SAVA.